US-based Delphi Consensus Study on Adjuvant Radiation Therapy (ART) in Node-Negative Cutaneous Squamous Cell Carcinoma (CSCC).

IF 7.4 1区 医学 Q1 ONCOLOGY
Jacqueline S Stevens, Christopher A Barker, Richard L Bakst, Carol Bradford, David R Carr, Bhisham Chera, Michelle Chen, Sunandana Chandra, Addison Demer, Heidi Donnelly, Bently Doonan, Thomas J Galloway, Jessica Geiger, Anokhi Jambusaria, Nikhil I Khushalani, Shlomo Koyfman, Justin J Leitenberger, Elizabeth Lilley, John Nicholas Lukens, Danielle Margalit, Theresa Medina, Devarati Mitra, Vinayak Muralidhar, Jonathan Paly, Itai Pashtan, Vishal Patel, Rosh Sethi, Monica Shukla, Ann W Silk, Divya Srivastava, Paul Swiecicki, Matthew Witek, Ashley Wysong, Sue Yom, Jonathan D Schoenfeld, Emily S Ruiz
{"title":"US-based Delphi Consensus Study on Adjuvant Radiation Therapy (ART) in Node-Negative Cutaneous Squamous Cell Carcinoma (CSCC).","authors":"Jacqueline S Stevens, Christopher A Barker, Richard L Bakst, Carol Bradford, David R Carr, Bhisham Chera, Michelle Chen, Sunandana Chandra, Addison Demer, Heidi Donnelly, Bently Doonan, Thomas J Galloway, Jessica Geiger, Anokhi Jambusaria, Nikhil I Khushalani, Shlomo Koyfman, Justin J Leitenberger, Elizabeth Lilley, John Nicholas Lukens, Danielle Margalit, Theresa Medina, Devarati Mitra, Vinayak Muralidhar, Jonathan Paly, Itai Pashtan, Vishal Patel, Rosh Sethi, Monica Shukla, Ann W Silk, Divya Srivastava, Paul Swiecicki, Matthew Witek, Ashley Wysong, Sue Yom, Jonathan D Schoenfeld, Emily S Ruiz","doi":"10.1016/j.ijrobp.2026.09.022","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>There is a paucity of high-level evidence for adjuvant radiation therapy (ART) in cutaneous squamous cell carcinoma (CSCC) creating practice variations. This study provides expert consensus recommendations on patient and tumor selection, timing, duration, dosage, and additional considerations for ART in node-negative CSCC.</p><p><strong>Methods: </strong>The Delphi panel included 35 experts in radiation oncology (15), dermatology/Mohs micrographic surgery (9), medical oncology (7), head and neck surgery (3), and surgical oncology (1). Consensus was defined as ≥80% concordance; near-consensus 70-79% concordance.</p><p><strong>Results: </strong>Consensus was reached to recommend ART when further surgery is not possible, but the tumor has positive gross or histologic/microscopic margins (35/35, 100%). Key consensus or near-consensus recommendations for recommending ART to the tumor bed following negative-margin surgery include: 5-year cumulative incidence of local recurrence (29/35, 83%) or nodal metastasis (27/35, 77%) ≥ 20%; gross cortical bone/marrow invasion (32/35, 91%); skull base invasion (32/35, 91%); 4 risk factors (RF) (35/35, 100%); 3 RF (30-33/35, 86-94%); PNI ≥ 0.1 mm and one other RF (30/35, 86%); and clinical nerve invasion (31/35, 89%). Immune status influenced ART decision-making (30/35, 86%) with 77% (27/35) more likely to recommend ART for immunosuppressed patients. Consensus was reached to omit ART for pathologic complete response following neoadjuvant immunotherapy (34/35, 97%). Among radiation oncologists, 100% (15/15) agreed the optimal window for ART to the tumor bed is 4-8 weeks and that hypofractionated regimens can be appropriate (12/15, 80%). Consensus was reached for prescription doses of 60-66 Gy in 2 Gy/fx (15/15, 100%) or 50-55 Gy in 2.5 Gy/fx (13/15, 87%), and that superficial radiation and brachytherapy are inappropriate ART modalities for node-negative high-stage CSCC (14/15, 93%). There was no consensus on elective nodal basin irradiation.</p><p><strong>Conclusions: </strong>This Delphi study provides an expert consensus-based framework to standardize ART for node-negative high-stage CSCC following surgery, informing future guidelines and utilization.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2026.09.022","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: There is a paucity of high-level evidence for adjuvant radiation therapy (ART) in cutaneous squamous cell carcinoma (CSCC) creating practice variations. This study provides expert consensus recommendations on patient and tumor selection, timing, duration, dosage, and additional considerations for ART in node-negative CSCC.

Methods: The Delphi panel included 35 experts in radiation oncology (15), dermatology/Mohs micrographic surgery (9), medical oncology (7), head and neck surgery (3), and surgical oncology (1). Consensus was defined as ≥80% concordance; near-consensus 70-79% concordance.

Results: Consensus was reached to recommend ART when further surgery is not possible, but the tumor has positive gross or histologic/microscopic margins (35/35, 100%). Key consensus or near-consensus recommendations for recommending ART to the tumor bed following negative-margin surgery include: 5-year cumulative incidence of local recurrence (29/35, 83%) or nodal metastasis (27/35, 77%) ≥ 20%; gross cortical bone/marrow invasion (32/35, 91%); skull base invasion (32/35, 91%); 4 risk factors (RF) (35/35, 100%); 3 RF (30-33/35, 86-94%); PNI ≥ 0.1 mm and one other RF (30/35, 86%); and clinical nerve invasion (31/35, 89%). Immune status influenced ART decision-making (30/35, 86%) with 77% (27/35) more likely to recommend ART for immunosuppressed patients. Consensus was reached to omit ART for pathologic complete response following neoadjuvant immunotherapy (34/35, 97%). Among radiation oncologists, 100% (15/15) agreed the optimal window for ART to the tumor bed is 4-8 weeks and that hypofractionated regimens can be appropriate (12/15, 80%). Consensus was reached for prescription doses of 60-66 Gy in 2 Gy/fx (15/15, 100%) or 50-55 Gy in 2.5 Gy/fx (13/15, 87%), and that superficial radiation and brachytherapy are inappropriate ART modalities for node-negative high-stage CSCC (14/15, 93%). There was no consensus on elective nodal basin irradiation.

Conclusions: This Delphi study provides an expert consensus-based framework to standardize ART for node-negative high-stage CSCC following surgery, informing future guidelines and utilization.

淋巴结阴性皮肤鳞状细胞癌(CSCC)辅助放射治疗(ART)的美国Delphi共识研究。
目的:缺乏高水平的证据表明,辅助放射治疗(ART)在皮肤鳞状细胞癌(CSCC)造成实践变化。本研究就淋巴结阴性CSCC的患者和肿瘤选择、时间、持续时间、剂量和其他考虑事项提供了专家共识建议。方法:由放射肿瘤学专家(15人)、皮肤病学/Mohs显微摄影外科专家(9人)、内科肿瘤学专家(7人)、头颈外科专家(3人)、外科肿瘤学专家(1人)组成的德尔菲专家组共35人。一致性定义为一致性≥80%;接近共识70-79%的一致性。结果:当不可能进一步手术时,一致建议ART,但肿瘤的大体或组织学/显微镜边缘呈阳性(35/35,100%)。阴性切缘手术后向肿瘤床推荐抗逆转录病毒治疗的关键共识或接近共识的建议包括:5年累积局部复发(29/35,83%)或淋巴结转移(27/35,77%)≥20%;大体皮质骨/骨髓侵袭(32/35,91%);颅底侵犯(32/35,91%);4个危险因素(RF) (35/35, 100%);3 rf (30-33/35, 86-94%);PNI≥0.1 mm和另一个RF (30/35, 86%);临床神经侵犯(31/35,89%)。免疫状态影响ART决策(30/ 35,86%),77%(27/35)的患者更有可能推荐ART。共识是在新辅助免疫治疗后病理完全缓解时省略ART(34/35, 97%)。在放射肿瘤学家中,100%(15/15)同意ART到肿瘤床的最佳窗口期为4-8周,并且低分割方案是合适的(12/15,80%)。2 Gy/fx的处方剂量为60-66 Gy (15/ 15,100%), 2.5 Gy/fx的处方剂量为50-55 Gy(13/ 15,87%),对于淋巴结阴性的高分期CSCC,浅表放疗和近距离治疗是不合适的ART方式(14/ 15,93%)。择期淋巴结盆照射尚无共识。结论:该德尔菲研究提供了一个基于专家共识的框架,以标准化淋巴结阴性晚期CSCC术后ART治疗,为未来的指导和应用提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书